Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia

Brandon Turunen, Craig Leach, Matthew Smith, Terra L. Lasho, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Yael Kusne, Talha Badar, James M. Foran, Aisha Margaert, Michelle Baptista, Stephanie Wiltzius, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 2771.

https://doi.org/10.1182/blood-2024-209024

Published: 2024

Journal Articles

Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service

Blood (2021) 138 (Supplement 1): 1254.

https://doi.org/10.1182/blood-2021-150169

Published: 2021

Journal Articles

Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service

Blood (2021) 138 (Supplement 1): 2321.

https://doi.org/10.1182/blood-2021-149685

Published: 2021

Journal Articles

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

Mhairi Copland, Daniel Slade, Graham McIlroy, Gillian Horne, Jennifer Byrne, Kate Rothwell, Kristian Brock, Hugues De Lavallade, Charles Craddock, Richard Clark, Matthew Smith, Rachel Fletcher, Rebecca Bishop, Dragana Milojkovic, Christina Yap

Blood (2021) 138 (Supplement 1): 312.

https://doi.org/10.1182/blood-2021-147972

Published: 2021

Journal Articles

Phenotypic and Functional Characterization of Multiple Myeloma By Single Cell Mass Cytometry (CyTOF)

Linda B Baughn, PhD, Erik Jessen, PhD, Matthew Smith, Neeraj Sharma, PhD, Joselle Cook, MBBS, Surendra Dasari, PhD, Kathryn E. Pearce, MS, Nathalie Meurice, PhD, Michael A. Linden, MDPhD, A. Keith Stewart, MB, ChB, P. Leif Bergsagel, MD, Brian G. Van Ness, PhD, Shaji K. Kumar, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141639

Published: 2020

Journal Articles

The Natural History of NPM1 MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)

Ing Soo Tiong, MBBS,FRACP,FRCPA, Richard Dillon, MA, PhD MRCP, FRCPath, Adam Ivey, BSc, MSc, PhD, Chung Hoow Kok, BSc, PhD, James Anton Kuzich, MBBS, Nisha Thiagarajah, MBBS, Ashish Bajel, FRACP, Nicola Potter, PhD, Matthew Smith, MBBS, Claire Hemmaway, Abin Thomas, Amanda Gilkes, Nigel H. Russell, MD, Andrew H. Wei

Blood (2020) 136 (Supplement 1): 25–27.

https://doi.org/10.1182/blood-2020-140296

Published: 2020

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Daniel Slade, MSc, BSc (Hons), Jenny Byrne, MD PhD, Kristian Brock, MSc, BSc, Hugues De Lavallade, Charles Craddock, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD, Matthew Smith, MBBS, Rebecca Bishop, BSc, Dragana Milojkovic, MBBS, MD, Christina Yap, MSci, PhD CStat

Blood (2019) 134 (Supplement_1): 497.

https://doi.org/10.1182/blood-2019-125591

Published: 2019

Journal Articles

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Blood (2018) 132 (Supplement 1): 5440.

https://doi.org/10.1182/blood-2018-99-118600

Published: 2018

Journal Articles

Mutations in SRSF2 Alter CSF3R Splicing in AML and Increase Expression of the V3 Variant Relative to V1

Lawrence J Druhan, PhD, Amanda Lance, MS, Carol G. Vestal, Andrea Price, Matthew Smith, Alicia Hamilton, Nury M Steuerwald, PhD, Belinda Rene Avalos, MD

Blood (2018) 132 (Supplement 1): 1106.

https://doi.org/10.1182/blood-2018-99-120000

Published: 2018

Journal Articles

Variable Penetrance Is Linked with Monoallelic Gene Expression in Inherited GATA2 -Mutated MDS/AML

Ahad Al Seraihi, BSc, MSc, Ana Rio-Machin, BSc, MSc, PhD, Kiran Tawana, MD PhD, Csaba Bödör, BSc, PhD, Shamzah Araf, MD, James A Heward, BSc, PhD, Matthew Smith, MBBS, MA, MRCP, MRCPath, MD, Sameena Iqbal, Steven Best, PhD, Nicholas Lea, PhD, Donal McLornan, MB, Bch (Hons), PhD MRCP, FRCPath, Alicia Ellison, BSc, Hemanth Tummala, PhD, Shirleny Romualdo Cardoso, BSc, Jamie D. Cavenagh, Tom Vulliamy, FRCPath, Inderjeet Dokal, MD FRCPCH, FRCPath, FMedSci, Jude Fitzgibbon

Blood (2016) 128 (22): 3916.

https://doi.org/10.1182/blood.V128.22.3916.3916

Published: 2016

Journal Articles

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

Rakesh Popat, MBBS, PhD, Sarah R Brown, Louise M Flanagan, Andrew Hall, Bhuvan Kishore, MBBS, FRPATH, MRCP, Matthew Streetly, Heather E Oakervee, Simon L. Hallam, Matthew Smith, MBBS, MA, MRCP, MRCPath, MD, Kwee L Yong, MBChB, PhD, Gordon Cook, MD PhD, James D. Cavenagh, MD

Blood (2015) 126 (23): 1826.

https://doi.org/10.1182/blood.V126.23.1826.1826

Published: 2015

Journal Articles

Disease evolution and outcomes in familial AML with germline CEBPA mutations

Blood (2015) 126 (10): 1214–1223.

https://doi.org/10.1182/blood-2015-05-647172

Published: 2015

Includes: Supplemental data

Journal Articles

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Kiran Tawana, MD, Aline Renneville, Jun Wang, PhD, Panayiotis Georgiades, Xavier Thomas, MD, Valerie Mialou, MD, Aleksander Savic, MD, Frederik W Van Delft, MD PhD, Jennifer G. Treleaven, MD, Sameena Iqbal, Norio Asou, MD, PhD, Naokuni Uike, MD, Konstanze Döhner, MD, Lars Bullinger, MD, PhD, Matthias Stelljes, MD, Csaba Bödör, PhD, James D. Cavenagh, MD, Doris Steinemann, PhD, Tim Ripperger, MD, Brigitte Schlegelberger, MD, PhD, Peter Vandenberghe, MD, PhD, Anne Uyttebroeck, MD, Josep F. Nomdedeu, MD, Henrik Hjorth-Hansen, MD, PhD, Rosemary E Gale, PhD, Cynthia L. Toze, MD, FRCP(C), Michael J. Barnett, BMBS, FRCPC, FRCP, FRCPath, Marianna Zombori, MD, Krisztian Kallay, MD, Jiri Pavlu, MD, Pim Mutsaers, MD, Fred H Menko, MD, Angela Thomas, PhD, FRCPath, FRCP, MB, BS, Christine Wright, MD, Jessica Okosun, MD, Chey Loveday, PhD, Pierre Fenaux, MD, PhD, Hamish Scott, PhD, Claude Preudhomme, Claude Chelala, PhD, Alison Male, MD, Carolyn J. Owen, MD, FRCPC, Matthew Smith, MD, PhD, Jude Fitzgibbon, PhD

Blood (2013) 122 (21): 740.

https://doi.org/10.1182/blood.V122.21.740.740

Published: 2013

Journal Articles

The Relationship of Depression and Anxiety and Impact of Cancer in Long-Term Survivors of Haematological Malignancy.

Ania Korszun, Rachel Johnson, Shah-Jalal Sarker, Chowdhury Kashfia, Charlotte Clark, Paul Greaves, MD, Judith Kingston, Gill Levitt, Janet Matthews, Rebecca Matthews, Matthew Smith, John G Gribben, T. Andrew Lister

Blood (2012) 120 (21): 3174.

https://doi.org/10.1182/blood.V120.21.3174.3174

Published: 2012

Journal Articles

A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report.

Dimitris A Tsitsikas, Dana Warcel-Sibony, Heather E. Oakervee, MBBS, BSc, MD, MRCP, FRCPath, Samir G Agrawal, Matthew Smith, David C Taussig, PhD, MRCP, FRCPath, Johannes de Vos, Elaine Stewart, Hannah Nicholas, John G. Gribben, MD, DSc, James D Cavenagh

Blood (2010) 116 (21): 3480.

https://doi.org/10.1182/blood.V116.21.3480.3480

Published: 2010

Journal Articles

Wilm’s Tumour 1 (WT1) Mutations Are Associated with FLT3-ITD Mutation and Poor Prognosis in Normal Karyotype AML.

Jude Fitzgibbon, Karin Summers, Ioannis Kakkas, Jane Stevens, Matthew Smith, Lan-Lan Smith, Gael Molloy, Finlay McDougal, Dominique Bonnet, Bryan D. Young, T. Andrew Lister

Blood (2006) 108 (11): 2302.

https://doi.org/10.1182/blood.V108.11.2302.2302

Published: 2006

Journal Articles

Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy.

Allan Lipton, Robert E. Coleman, Pierre Major, Janet E. Brown, Ker-Ai Lee, Matthew Smith, Fred Saad, YinMiao Chen, Yong Jiang, Hei, Richard Cook

Blood (2005) 106 (11): 3456.

https://doi.org/10.1182/blood.V106.11.3456.3456

Published: 2005

Journal Articles

Prognostic Significance of Biochemical Markers of Bone Metabolism in Patients with Bone Lesions from Multiple Myeloma (MM).

Richard J. Cook, Robert E. Coleman, Pierre Major, Allan Lipton, Janet E. Brown, Ker-Ai Lee, Matthew Smith, Fred Saad, YinMiao Chen, Yong Jiang Hei

Blood (2005) 106 (11): 5015.

https://doi.org/10.1182/blood.V106.11.5015.5015

Published: 2005

Journal Articles

Flow Cytometric FLT3 Expression in Acute Leukaemias Is of Diagnostic Value but Does Not Correlate with ITD / D835Y Mutation Status.

Colin Ridler, Matthew Smith, Tim Milne, Fatema Ebrahim, Marion Macey, T. A. Lister, Jude Fitzgibbon, Jamie D. Cavenagh, Samir G. Agrawal

Blood (2004) 104 (11): 3014.

https://doi.org/10.1182/blood.V104.11.3014.3014

Published: 2004

NARROW

Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia

Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service

Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

Phenotypic and Functional Characterization of Multiple Myeloma By Single Cell Mass Cytometry (CyTOF)

The Natural History of NPM1 MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Mutations in SRSF2 Alter CSF3R Splicing in AML and Increase Expression of the V3 Variant Relative to V1

Variable Penetrance Is Linked with Monoallelic Gene Expression in Inherited GATA2 -Mutated MDS/AML

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

Disease evolution and outcomes in familial AML with germline CEBPA mutations

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

The Relationship of Depression and Anxiety and Impact of Cancer in Long-Term Survivors of Haematological Malignancy.

A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report.

Wilm’s Tumour 1 (WT1) Mutations Are Associated with FLT3-ITD Mutation and Poor Prognosis in Normal Karyotype AML.

Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy.

Prognostic Significance of Biochemical Markers of Bone Metabolism in Patients with Bone Lesions from Multiple Myeloma (MM).

Flow Cytometric FLT3 Expression in Acute Leukaemias Is of Diagnostic Value but Does Not Correlate with ITD / D835Y Mutation Status.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only